You can buy or sell VTGN and other stocks, options, ETFs, and crypto commission-free!
VistaGen Therapeutics, Inc. Common Stock, also called VistaGen Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines for depression and other diseases and disorders of the central nervous system. Read More It focuses on AV-101 product, an oral, non-opioid and non-sedating therapy that offers the potential to be a new at-home treatment for multiple central nervous system indications with high-unmet medical need. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMar 19
VistaGen Therapeutics (VTGN) Investor Presentation - Slideshow
The following slide deck was published by VistaGen Therapeutics, Inc. in conjunction with this event. 1 36 Click to enlarge Notes:...
Yahoo FinanceFeb 27
Four Tech Stocks Looking To Test February Highs
CORAL GABLES, FL / ACCESSWIRE / February 27, 2019 / Nothing in life is guaranteed, but based on the first few months of the year, the future of the tech stock market looks to be in good shape.
Stock Price, News, & Analysis for Vistagen Therapeutics
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemica...
Expected Jun 26, After Hours